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Abstract
BACKGROUND: In the United States, lung cancer has the highest mortality rate of all other
cancers among men and women. Kentucky is ranked 50th among all states, leading the nation
in new lung cancer cases each year. Lung cancer screening using Low dose Computed
Tomography (LDCT) can reduce lung cancer-related morbidity and mortality. Lack of smoking
history documentation to identify eligible patients is a major contributing factor to low national
screening rates. Obtaining complete smoking history remains the most important technique in
identifying candidates for lung cancer screening.
PURPOSE: The purpose of this quality improvement project was to evaluate the rates of
complete smoking history documentation and LDCT orders in one primary care setting after
implementing evidence-based interventions to improve documentation and screening rates.
METHODS: This quality improvement project followed a quasi-experimental design. Using the
FOCUS-PDSA as the improvement model, baseline data for complete smoking history
documentation and LDCT orders were analyzed, and a target goal was set. A total of three
rapid cycles of change using evidence-based improvement strategies (patient information
poster in exam room, staff education, and clinical reminder cards) were implemented and
evaluated to assess changes in the amount of smoking history documentation recorded and
lung cancer screening orders after each cycle.
RESULTS: Smoking history documentation throughout the study improved significantly (p =
.039). Documentation was significantly higher after the final cycle (PDSA cycle 3) compared to
both cycle 1 (p=.022) and cycle 2 (p=.010) There was no significant difference in LDCT orders
over the three cycles (p=0.248). There was minimal improvement overall when evaluating
accurate documentation with ordering LDCT (p=0.30).
CONCLUSION: Through the combination of interventions used, there was a significant
increase in smoking history documentation throughout the study. No specific intervention used
was found to have a significant improvement independently. LDCT orders were not affected
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substantially by the interventions used in combination with each other or individually. The
results suggest that the use of clinical reminders had the greatest improvement in LDCT
orders overall and had a significant increase in former smokers’ lung cancer screening orders
within the chosen clinic.
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Problem Description
Lung cancer has the highest mortality rate of any cancer among both men and women
(CDC, 2017). The American Cancer Society estimates that there will be 236,740 new cases of
lung cancer and 130,180 lung cancer deaths in 2022 (ACS, 2022). Kentucky leads the nation in
new lung cancer cases each year (U.S. Cancer Statistics Working Group, 2018). Kentucky has
the highest lung cancer rate in the nation. Cigarette smoking is linked to roughly 80 to 90
percent of lung cancer deaths in the United States (CDC, 2018). Kentucky’s smoking rate (24%)
is ranked significantly higher than the national rate (15%). Among all other states, Kentucky has
the second highest smoking rate in the nation, ranking next to last with West Virginia (ALA,
2022). The CDC reported in 2017 that tobacco use remains the leading preventable cause of
death nationally and globally.
Early detection with Low dose Computed Tomography (LDCT) can reduce morbidity and
mortality by 20% by improving prognosis and increasing treatment options (De Koning, et al.,
2020). Lung cancer screening is the key to diagnosing lung cancer early when the disease is
most curable, but only 21% of new lung cancer cases in Kentucky are caught at an early stage
before the cancer has spread to other organs and treatment options become limited (ACS,
2022). To ensure at-risk patients are identified and screened via LDCT, there must be accurate
and complete smoking history documentation so eligibility for LDCT can be determined;
however, it is not occurring at the rate it should be. The Healthy People program is a nationally
driven program to improve the overall well-being of Americans over the next decade. The
national target from Healthy People 2030 is to increase lung cancer screenings to 7.5%, but
currently, the national rate of eligible patients being screened is below the target at 5.7%
(Healthy People 2030, 2017). Kentucky’s screening rate is 13.7%, which is higher than the
national rate but is substantially lower than national screening rates for other cancers such as
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colorectal cancer at 63%, breast cancer at 50%, and prostate cancer at 35% (ACS, 2020; ALA
2021).
Lung cancer screening has an estimated 1.5% positivity rate nationally. Meaning for
every 1,000 people screened, 15 will be diagnosed with lung cancer (Young, Fairchild & Hefner,
2017). In 2020 it was estimated that 8.51 million Americans were eligible for lung cancer
screenings (Fedewa et al., 2021). With a national screening rate of 5.7%, only 485,070
estimated eligible Americans would have received their screening, and 7,276 would be
diagnosed with lung cancer. Compared to the breast cancer screening rate of 50%, if 50% of
eligible patients received their lung cancer screening an estimated 4,255,000 patients would be
screened with LDCT and at a 1.5% positivity rate, 63,825 of these patients would be diagnosed
with lung cancer. The screening difference between current lung cancer screening rates (5.7%)
and breast cancer screening rates (50%) is missing over 3.7 million eligible screenings and
56,549 Americans having lung cancer undiagnosed. This is significant because many
individuals that are eligible for screening and could have lung cancer are being missed which
leads to late detection and limited treatment options. Even though lung cancer is the second
most diagnosed cancer, the mortality rate is higher than breast, prostate, and colon cancer
combined (ACS, 2019). Screening rates must improve, the necessary antecedent of improving
screening is to improve smoking history collection.
The 2013 lung cancer screening guidelines, created by the United States Preventative
Services Task Force (USPSTF), recommended LDCT of the chest for lung cancer screening
instead of a conventional chest computerized tomography (CT) (USPSTF, 2013). In comparison
to the conventional chest CT, the LDCT dispenses 90% less radiation and is a more costeffective approach, leading to early detection and improved outcomes (Radiologic Society of
North America, 2018). Lung cancer screening has been around since the 1960s, but screening
with LDCT has only been in practice since 2015 and just recently gained Medicare coverage.
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Medicare coverage for lung cancer screenings is only available in 40 states, including Kentucky.
(ALA, 2021). In March 2021, USPSTF updated its lung cancer screening guidelines. The newest
recommendations are annual LDCT of the chest for adults 50 to 80 years old who have a 20
pack-year smoking history and are currently smoking or have quit within the last 15 years
(USPSTF, 2021). This recommendation replaced the 2013 USPSTF guideline that
recommended annual LDCT of the chest for adults aged 55 to 80 years who have a 30 packyear smoking history and are currently smoking or have quit within the last 15 years. The
newest recommendations increased the age range and lowered pack-year eligibility criteria. The
expansion of guidelines in 2021 will aid in identifying more eligible candidates that will in turn
optimistically increase screening rates and decrease mortality related to lung cancer (USPSTF,
2021).
Despite the USPSTF recommendations, screening rates remain low due to multiple
factors identified in the literature. These factors include limited smoking history documentation,
poor provider knowledge of screening guidelines, insurance and cost barriers, lack of patient
awareness about screening, and low access to screening centers (Caudill, 2019; Couglin, et al.,
2020; Davenport, 2018; Eberth, 2014; Lewis et al., 2015; Modin et al., 2017; Pham et al., 2018;
Raz et al., 2018; Rodriquez, 2019; Schiffelbein, et al., 2020; Simmons et al, 2017; Triplette et
al., 2018; Wang et al., 2019). Healthy People 2030 has identified a goal to decrease lung cancer
mortality by 10% by 2030. The strategy to decrease mortality is to increase screening rates.
Strategies incorporate public campaigns to promote awareness and knowledge of screening by
using decision-making aids (Hamann et al., 2018; Schiffelbein, et al., 2020; Simmons et al,
2017). The Kentucky state government is committed to reducing lung cancer mortality by being
proactive and supporting the availability and quality of screening (Fedewa, et al., 2021). This
resulted in the development of the Kentucky LEADS Collaboration. This initiative was created to
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reduce the burden of Lung Cancer by increasing Education, Awareness, Detection, and
Survivorship (LEADS) to the public (Kentucky LEADS Collaboration, 2021).
Lung cancer screening rates remain low due to multiple factors despite the
recommended guidelines for screening. Overcoming the barriers to lung cancer screening is
essential to increase screening rates. Identifying eligible patients is the leading modifiable factor
to low screening rates largely due to the incomplete documentation of smoking history (Pham et
al., 2018). This project will focus on the importance of complete smoking history documentation
to increase eligibility for screening, in hopes of increasing LDCT screening rates.
Purpose
The purpose of this quality improvement (QI) project was to evaluate rates of complete
smoking history documentation and LDCT orders in a primary care setting after implementing
evidence-based interventions to improve documentation and screenings rates.
Objectives
−

Identify existing barriers to obtaining complete smoking history documentation.

−

Evaluate changes in complete smoking history documentation after implementation of
rapid cycles of evidence-based change strategies

−

Evaluate changes in LDCT orders after implementation of rapid cycles of evidencebased change strategies.
Theoretical Framework

Change Theory
The theoretical framework applied to this QI project was the Change Theory created by
Kurt Lewin in 1947. Lewin proposed that change in behaviors will occur from changes in the
forces or energies within the environment (Lewin, 1947). His theory divides the change process
into three stages: unfreeze, change, and refreeze. This model offers an approach that can help
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identify the need for change, navigate through the change process, and achieve a desired goal
or outcome (Bozak, 2003).
The initial step of the framework has been labeled the “unfreeze” stage, which identifies
the need for change and prepares for a change to occur. During this step, evidence is needed to
support an intervention that will improve patient outcomes. This step is deemed the most difficult
due to challenging individuals' normalcy by reconstructing the driving forces behind the
intervention. The second step of the framework is labeled the “change” stage, which
strengthens the driving forces by implementing initiatives to bring about positive organizational
change. The last step of the framework is labeled the “refreezing” stage, where change has
occurred, and the next step is to maintain (refreeze) the change in process. This step is
maintained through policy, education, or rewards to ensure this change in practice is continued.
The three stages of this theory ensure the problem is identified, a process for change is
implemented, and change is maintained.
This study utilized the framework to positively impact change in this QI project. First,
during the unfreeze stage identify the driving forces behind low lung cancer screening rates.
This QI project expanded on the evidence supporting the disparity of lung cancer screening
eligibility being affected significantly by inadequate smoking history documentation, as well as
identified clinic-specific barriers via survey. During the change stage, strategies were developed
to improve adherence to screening and trialing interventions through each PDSA cycle. The
refreezing process occurs once recommendations are made to improve assessment and
documentation of smoking history and increase lung cancer screening rates.
FOCUS- PDSA
The FOCUS PDSA model consists of two stages that guide the interventions. The first
stage is the FOCUS stage, where an action plan is created. The FOCUS portion of this project
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is an acronym for: Find a process to improve, Organize a team, Clarify current knowledge,
Understand the cause, and Select a process to improve (IHI, 2019).
The second stage is the PDSA stage, in which four steps are utilized to create the cycles
which implement change. The PDSA (Plan-Do-Study-Act) has rapid cycles that can change
quickly, depending on the results of the previous cycle focusing on change within the area of
improvement. The purpose of these rapid cycles of change is to decide whether the proposed
change is effective without disrupting the clinic. The first component of the model is “Plan.”
During this step plan development for the project occurs. The second component is “Do”. This
step entails small cycles of change to implement the plan. The third component is “Study”.
During this phase, data of the implemented change is collected from step two (Do) and
analyzed. The fourth component is “Act”. Based on the data gathered from step three,
modifications are made to refine the change in anticipation of improvement. The PDSA model is
repeated multiple times and focuses on areas of improvement from the previous cycles.
Figure 1. FOCUS-PDSA Model
Find a process to improve

Plan development

Organize a team

Do small interventions to create change

Clarify current knowledge

Study the data collected and analyze.

Understand the cause

Act on intervention once integrating modifications

Select a process to improve

(IHI, 2019).
Review of Literature

The goal of this literature review was to conduct a comprehensive review focusing on
barriers to lung cancer screening in eligible adult patients in the primary care setting, as well as
strategies to improve screening. PubMed and CINAHL was systematically searched from 2004
through 2021. A review of Pub Med and CINAHL database was preformed using the following
combinations of search terms: lung cancer screening, smoking, tobacco, documentation,
barriers, provider knowledge, adherence, compliance, eligibility, gaps. The literature search
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covered a wide range of study types, including randomized controlled trials (RCTs), case-control
studies, interrupted time series, cohort studies, and cross-sectional studies and qualitative
studies. It included studies that were conducted in the United States and internationally,
including those conducted in developing countries. The search was limited to articles written
about adults aged 18 or older and written in English. Studies published in English with free full
text available were also used. Exclusion criteria were studies in a language other than English,
and studies in the pediatric or adolescent population.
Synthesis of Evidence
Empirical evidence supports screening for lung cancer using LDCT as an effective way
to reduce preventable mortality in individuals with a significant smoking history. Screening rates
remain low, and the literature provides many factors that lead to this. The literature identified the
three commonalities for low lung cancer screenings as inadequate smoking history
documentation (Caudill, 2019; Davenport, 2018; Modin et al., 2017; Triplette et al., 2018),
provider knowledge on screening guidelines (Couglin, et al., 2020; Raz et al., 2018; Simmons et
al., 2017), and lack of patient knowledge of screening (Couglin, et al., 2020; Eberth, 2014; Lewis
et al., 2015; Schiffelbein, et al., 2020; Simmons et al, 2017). Identifying an eligible screening
candidate begins with recognizing their smoking status and pack-year history. In assessing
smoking status, using comprehensive language is important to ensure former smokers are
accounted for during screening (Raz et al., 2014).
The gap in provider knowledge of up-to-date guidelines and eligibility criteria contributes
to lower utilization of lung cancer screening (Couglin, et al., 2020; Raz et al., 2018; Simmons et
al., 2017). In 2016, a study reported that nearly two-thirds of the primary care providers in South
Carolina could not accurately state the current guidelines (Ersek et al., 2016). Besides smoking
status, additional critical details are often not assessed which limits eligibility due to patients not
meeting minimal pack-year documentation. Other factors include lack of understanding of
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screening eligibility, inadequate smoking history documentation, and appointment time
constraints which led to limited clinical time to address lung cancer screening eligibility in
addition to other current medical issues (Raz et al., 2018; Simmons et al., 2017; Triplette et al.,
2018).
Lack of patient knowledge of screening prevents some eligible patients from being
screened (Couglin, et al., 2020; Eberth, 2014; Lewis et al., 2015; Schiffelbein, et al., 2020;
Simmons et al, 2017). Inadequate awareness of screening could be deemed insignificant by the
vulnerable population due to a lack of understanding of their true risk which ultimately leads to
poor health outcomes. Increased public awareness with educational materials and signs in
outpatient offices can stimulate communication between patients and providers to create shared
decision-making on their screening eligibility (Hamann et al., 2018; Schiffelbein, et al., 2020;
Simmons et al, 2017).
The lack of complete smoking history documentation has been identified in the literature
as the leading factor in low lung cancer screening rates (Caudill, 2019; Davenport, 2018; Modin
et al., 2017; Triplette et al., 2018). The issue that arises is insufficient details in the smoking
history collection including smoking status, former smokers quit date, amount, and length of
tobacco use which is required to calculate pack years. Pack-year documentation is potentially
the most important component of an individuals’ lung cancer screening eligibility determination
(Modin et al, 2016). In a similar study, it was found that complete documentation of tobacco
history (including pack-years) increased LDCT orders (Caudill, 2019). The incorporation of
inclusive, meaningful language/questions can improve history collection and aid in identifying
eligible screening candidates (Raz et al., 2014). Creating a standardized process for smoking
history data collection will improve EMR data quality while ensuring all patients are identified
when eligible for screening (Modin et al., 2016). Overall, inadequate smoking history
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documentation is a modifiable factor that could be improved with adequate resources and
education (Triplette et al., 2018).
Improved patient rooming procedures and the use of screening reminders are the
leading interventions to combat inadequate smoking history documentation (Couglhin, et al.,
2020; Johnson et al., 2017; Polubriaginof, Salmasian, Albert, & Vawdrey, 2018; Modin et al.,
2016). Since the initiation of EMRs, smoking status documentation has improved (Chen et al.,
2013; McGinnis et al., 2011; Modin et al., 2017). Yet, EMR documentation on smoking history is
highly vulnerable to inaccuracies leading to missed opportunities in identifying eligible patients
for screening (Modin et al., 2017). Improving rooming procedures to incorporate standardized
documentation in the EMR of smoking history would increase documentation rates. This
intervention could allow more accurate state and national data collection, in addition to
identifying eligible patients for LDCT to reduce mortality from lung cancer.
Summary of Evidence
The studies synthesized for this QI project analyzed barriers affecting the lung cancer
screening rate. The findings between studies identified the main barriers to lung cancer
screening included inadequate smoking history documentation, poor provider knowledge of
screening guidelines, and lack of patient knowledge of screening options and eligibility criteria.
Evidence revealed that obtaining a complete smoking history is a key element in determining
eligibility and prompting providers to initiate screening orders while educating patients of their
eligibility and screening protocol.
Gaps in Knowledge
Lung cancer screening is an essential part of health maintenance. Despite the USPSTF
recommendations, the leading factor hindering eligibility is inadequate smoking history
documentation. Only 5.7% of the eligible population received lung cancer screenings in 2021,
according to the American Cancer Society (ACS, 2021). Documentation compliance is a key
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element in identifying eligible patients. Providers represent the key component of screening
implementation. Providing the clinic staff with education and the tools to complete smoking
history documentation will in hope improve screening rates and implementation.
Methods
Design
The goal of this project was to improve lung cancer screening by improving eligibility
recognition through complete smoking history documentation. This QI project followed a quasiexperimental design. The project followed the FOCUS-PDSA model which was used to identify
opportunities for improvement and use a planned approach to implement change.
Setting
This project took place in an urban family medicine clinic located in Kentucky that
provides primary care services to patients of all ages. The clinic office space was used to
conduct this research. This facility is easily accessible from most parts of Lexington, KY, and
includes free parking. This clinic offers primary care, prevention, and continuity care for patients.
Congruence of project to selected agency’s mission/goals/strategic plan
The University of Kentucky is dedicated to improving people’s lives across the Bluegrass
through economic development, research, and healthcare. Their mission is to provide quality
health care to all in a manner that serves those in need by sharing and applying knowledge.
Improved tobacco history screenings will increase the identification of eligible patients for lung
cancer screenings and can reduce morbidity and mortality related to lung cancer.
Stakeholders
Multiple stakeholders are involved in the improvement of tobacco history screening
including medical assistants (MA), providers, and patients. The medical assistants ensure all
patients are screened and that documentation is current and up to date. Providers are
responsible for providing care, education, and referrals for eligible patients. The patient must
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actively participate in the care to allow for open communication to prevent setbacks from
barriers.
Other stakeholders include the University of Kentucky lung cancer screening program
staff, insurance companies, and the clinical leadership with the ability to use the EMR to track
data and who are held accountable for clinical outcomes. The University of Kentucky provides
Kentuckians with the opportunity of early detection and treatment with proper care coordination
in the lung cancer screening program. The insurance companies are stakeholders because of
the need to ensure the cost of screening is covered by the patient’s insurance. The Epic EHR
has components that can compute and sense data that can improve the delivery of healthcare.
Barriers and Facilitators Identified
Facilitators at the clinic include the clinic’s focus on promoting health screenings and
preventing health problems as well as improving the quality of care for all patients. This clinic,
as well as all other UK facilities have Epic EHR which allows for access to current care gaps
including past due screenings for each patient, as well as the ability for the use of clinical
reminders.
Time constraints of patient visits, lack of patient knowledge of screening, lack of smoking
history documentation, and providers’ unfamiliarity with screening guidelines were all identified
in the survey as barriers to effective screening. Barriers to identifying eligible candidates for lung
cancer screening included time constraints during patient visits leading to a lack of time to
screen effectively, as well as providers not being notified of a positive screening identified during
the rooming process in which the MA obtained and documented a complete smoking history.
Sample
Target Population: Clinic staff
Inclusion criteria included medical assistants and providers, aged over 18 years old, that
were currently employed at the clinic. Participants could have been of any race, ethnicity, or
21

gender. The clinic personnel were not included in the prospective chart review. Data was
collected from staff via an anonymous survey.
Secondary Target Population: Lung cancer screening eligible patients
Inclusion criteria included all clinic patients 50 – 80 years of age that were current or
former smokers, and residents of Kentucky. Participants could be of any race, ethnicity, or
gender and have any or no health insurance.
Exclusion criteria included pediatric patients, children, and adults under the age of 50
and over the age of 80, or non-Kentucky residents. There was no direct interaction with patients,
only patient charts that met inclusion criteria were reviewed for data collection.
Enrollment
The enrollment date for this research project was November 2021 to January 2022. The
retrospective chart review included charts from November 2021 while the prospective review
period was from December 2021 to January 2022. The sample population used throughout this
study was a convenience sample for the period in which data was collected. The sample during
the retrospective baseline chart review was 20 adult patients meeting the following eligibility
criteria: 50- to 80-year-olds who have a 20 pack-year smoking history and are currently smoking
or have quit within the last 15 years. The prospective chart review was composed of 60 adult
patient charts divided between the 3 PDSA cycles (20 charts each cycle). A total of 80 patient
charts were reviewed during this QI project. In addition, 10 clinic staff members were included in
this study.
Procedure
Institutional Review Board Approval
Institutional Review Board (IRB) approval was obtained for this expedited study.
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Measures and Instruments
The collection of data was completed using a chart audit to quantify pre- and postmeasures on smoking history documentation and LDCT orders. The barriers in the clinic were
assessed electronically using a survey created by the PI and entered in the Qualtrics. The
survey had a total of six questions, including both Likert scale and open-ended questions. The
questions ranged from personal perceived barriers, ranking of clinic barriers, the question used
when assess smoking history, and improvements they felt would make the most impact on low
screening rates. Qualtrics was used to create a survey to allow the survey to be sent and
completed electronically to ensure the survey was easily accessible. This anonymous, voluntary
survey was distributed via email to clinic staff with a cover letter (Appendix A) and a link to the
survey. The survey was used to evaluate the barriers and adherence of staff to screening all
eligible patients. Data were analyzed through inferential and descriptive statistics to calculate a
measurable outcome.
Description of Evidence-Based Interventions
Stage One: Plan Development
Find a Process to Improve
The focus of this project was improving rates of lung cancer screening using LDCT.
Clarify Current Knowledge
Despite the USPSTF recommendations, screening rates remain low due to multiple
factors, with inadequate smoking history documentation being identified as the leading factor.
The first step was to clarify the current process for screening for lung cancer within the chosen
clinic. The PI completed an in-depth review of the clinic's current practices by personally
examining and creating a process map of the clinic’s flow (Appendix E). The rooming process,
as well as providers’ assessment was evaluated to identify the barriers to effectively screening
all eligible patients. During the rooming process, the MA obtains vitals, establishes the chief
23

complaint, and completes the patient’s history, including their smoking history. Once the MA is
finished, they leave the room and the provider enters to review the patient’s chief complaint,
perform a physical exam, discuss a treatment plan, and assess necessary gaps in health
maintenance. If the provider deems the patient eligible for LDCT screening, they have a shared
decision-making conversation with the patient and if willing, LDCT is ordered. In theory, the
process is fine, yet the issue is that this process is not always followed.
Understand the Problem
A voluntary survey (Appendix B) was sent to all MAs and providers to explore the
barriers that contribute to the low screening rate for lung cancer. The barriers identified guided
the processes to improve all cycles (Figure 3). The main factors identified were the need for
increasing patient awareness of screening guidelines, improving smoking history
documentation, and increasing the clinical staff’s knowledge of screening guidelines. This
decided the selection of evidence-based strategies to improve the screening rates.
Select a Process to Improve
The process to improve was the improvement in LDCT orders, which relies on complete
documentation being completed. A smart goal was created to ensure there was a specific,
measurable, attainable, relevant, and time-bound goal.
SMART GOAL: The goal of this quality improvement project was to improve smoking
history documentation of screening guidelines to increase lung cancer screening orders by 3%
for all eligible patients by the end of January 2022.
Stage Two: Implement Plan
The PDSA model uses rapid cycles of change that helped guide the processes of the
following cycles. The processes selected for improvement were to increase patients’ awareness
of screening guidelines, improve smoking history documentation and knowledge of screening
guidelines due to the barriers identified by staff via survey. Providers and MAs at the chosen
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clinic helped with implementing the interventions. The MA helped implement complete smoking
documentation during the rooming procedure by using a more inclusive question ["Do you
smoke or have you ever smoked"] to ensure former smokers were being screened
appropriately. The providers implemented lung cancer screening orders on eligible patients.
The first PDSA cycle was to increase patient awareness of the screening tool and
criteria eligibility. The intervention chosen was a lung cancer screening poster that discussed
the screening guidelines, how to document pack years, and the pros and cons to screening in
an understandable language to patients (Appendix C). This cycle did not measure the patient’s
awareness, yet to assess lung cancer screening rates with anticipation of provoking
communication between patients and providers to discuss their screening eligibility. This
intervention aimed to assess if there was an improvement of documentation and LDCT by
increasing awareness and provoking conversations with staff.
The second PDSA cycle was built upon cycle one by incorporating an educational
intervention with clinic staff, in addition to the informational patient poster. Verbal feedback was
collected from clinic staff after cycle one, that revealed they thought the poster helped promote
patient awareness. However, complete smoking history documentation remained inadequate
resulting in low LDCT ordering rates. This cycle focused on improving complete smoking history
documentation and increasing awareness of screening eligibility criteria. Pack year
documentation quantifies smoking history by indicating a patient’s cumulative tobacco
consumption. This is measured by the number of packs of cigarettes smoked per day multiplied
by the years the patient has smoked. This measurement is an important factor in determining
lung cancer risk, as well as part of the guideline criteria. The 2021 USPSTF lung cancer
screening guidelines include annual LDCT of the chest for adults 50 – 80 years old, with a 20pack year history, and either currently smoke or quit in the last 15 years. The use of inclusive
language can mitigate the stigma of smoking and can illuminate the full complex smoking
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history. Using a more invasive question such as, “Do you smoke or have you ever smoked”,
eliminates not accounting for former smokers during screening. The use of more meaningful
questions can result in more complete data collection and aid in identifying more eligible
patients.
The third PDSA cycle continued to build off the previous two cycles and was not
identified initially. The barrier identified was that there was a gap in communication between the
MA obtaining a positive smoking history and the provider who assessed the patient. Although
documentation of smoking history improved (which identifies patients eligible), the gap identified
was that the provider did not always review the smoking history. Modifications were made to
increase communication between the MA and the provider related to patients’ smoking history.
A cue to action needed to be created to alert the provider to order lung cancer screenings on all
eligible patients identified during the rooming process. The flow of the clinic did not have a
process to communicate or alert the provider of an eligible screening candidate once the
smoking history was obtained. Before this intervention, the MA would write orders on a 16x20
whiteboard outside the exam room to alert the provider of the reason for the visit and the orders
needed. LDCT orders were not included on the whiteboard due to unawareness of screening
eligibility with smoking history documentation. The intervention that was implemented was the
use of a visual clinical reminder to alert the provider that the patient was deemed eligible for
lung cancer screening once obtaining a positive smoking history. The MA collected the smoking
history during the rooming process and placed a 4x6 inch laminated bright pink card on the
exam room door to notify the provider of the patient’s eligibility due to their smoking history
(Appendix D). This allowed the provider to be conscious of eligibility which could prompt shared
decision-making conversations about screening with the patient. A second educational session
was created to provide a reminder of the initial educational session, in addition to how to use the
signs on the doors. An in-person presentation was used to educate the MA’s on how to use the
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sign. An in-person conversation took place with the providers to make them aware of the sign
and how it would be used. All staff not available for the in-person presentation/conversation
were sent an email with the educational material.
Data Collection
The data collected was stored on a password-protected Share point site accessed
through a HIPPA protected server. The Qualtrics survey to assess clinic-specific barriers was
available to clinic staff for 2 weeks. The electronic health record, EPIC, was used to collect data
during the chart review. The collection of data was completed using a chart audit which
quantifies pre- and post-measures on smoking history documentation and LDCT orders. The
quantitative data collected during each cycle included the medical record number (MRN),
provider seen, current smoking status, completion of complete smoking history documentation,
and LDCT order. All data was collected and recorded in an Excel spreadsheet and was stored
on a password-protected Share point site accessed through a HIPPA protected server. All
patient identifiers were removed from data collection except MRN. The MRN was collected to
ensure that the identified patients were notified of their screening eligibility once the research
study was completed.
The clinic's baseline data was collected in November 2021 before any interventions
occurred. The first PDSA cycle interval lasted 14 days and the data collection occurred in
December 2021. There was a 3-day lapse between each cycle to analyze data and create the
next cycle. The second PDSA cycle interval lasted 26 days. The second cycle interval was
extended due to the clinic being closed for the holidays, as well as closing one day for extensive
COVID cases within the clinic. The collection of data for cycle two occurred in January 2022.
There was a 4-day lapse between this cycle to analyze data and create the next cycle. The third
PDSA cycle interval lasted 22 days and the data collection occurred in February 2022.
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Data Analysis
Qualitative and quantitative data were collected through the survey using both Likert
scale questions (quantitative), as well as open-ended questions (qualitative) which were
analyzed and synthesized to identify clinic barriers. The data from the survey and reviewed
literature is what guided the PDSA cycles. Data from this investigation were analyzed using
SPSS statistical software. Data was analyzed through inferential and descriptive statistics to
calculate measurable outcomes. The cycles were compared to determine statistically significant
results to suggest the effectiveness of each intervention. Accurate smoking history and LDCT
orders of each cycle were compared to preintervention data to determine significance.
Feasibility and Sustainability
This project did not require a budget, or commitments from patients for interactions. The
educational intervention was completed by the PI during the clinic lunch hour, which was
identified by staff as feasible to have the ability to attend. Staff commitment to attend the
educational intervention was voluntary, yet practical due to the timing and location of the
intervention. The intervention of the clinical reminder for lung cancer screening is a sustainable
intervention due to the absence of continuous cost once appropriate reminders were created
due to the lamination of the reminder to ensure longevity. The proposed interventions evaluation
of sustainability was limited due to time frame restrictions on the project’s completion.
Sustainability is inherently tied to accountability. Once the process is in place and awareness of
screening guidelines are improved, the process should automatically continue due to
heightened accountability through data tracking and performance data. Increasing accountability
by assigning someone a specific responsibility can ensure the focus of stakeholders are upheld
(Newell, P. & S. Bellour, 2002).
Once this project was completed, a meeting with the staff occurred to discuss all aspects
of successes, failures, and improvements of interventions. Continuing the educational
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intervention with clinic staff would be sustainable due to the simplicity of adaptation and
flexibility of the educational material to be presented. Sustainability can be maintained by the
continuation of posters within the rooms on lung cancer screening, improved documentation,
and the use of clinical reminders already in place. Interventions would need to be evaluated to
determine long-term sustainability within the clinic and other health care facilities.
Results
The study included a total of 80 patients who met inclusion criteria, divided as 20 for
baseline assessment, 20 for cycle one, 20 for cycle two, and 20 for cycle three. The range of
pack years from all patient participants was from 20 – 104 and the median pack-year
comparison of all cycles was 30.5 (Table 1).
Table 1. Descriptive summary of patient characteristics (N = 80)
Preintervention
(n = 20)

PDSA Cycle 1
(n = 20)

PDSA Cycle 2
(n = 20)

PDSA Cycle 3
(n = 20)

Provider,
(n=of
patients seen%)
Provider 1
7 (35%)
2 (10%)
Provider 2
1 (5%)
3 (15%)
1 (5%)
Provider 3
2 (10%)
1(5%)
3 (15%)
6 (30%)
Provider 4
2 (10%)
5 (25%)
6 (30%)
3 (15%)
Provider 5
4 (20%)
6 (30%)
5 (25%)
7 (35%)
Provider 6
4 (20%
3 (15%)
5 (25%)
4 (20%)
Smoking Status
Current
12 (60%)
13 (65%)
7 (35%)
12 (60%)
Former
8 (40%)
7 (35%)
13 (65%)
8 (40%)
Pack years,
26.0 (20-73)
21.0 (20 – 90)
40.5 (20 – 98)
40 (20 – 104)
median* (range)
*Median was reported over the mean due to the right-skewed distribution of pack years.
Preintervention Results
During the preintervention data collection, the clinic staff were unaware of the study
being preformed. A total of six providers were evaluated and a total of 20 patients that met the
criteria during the convenience sample period were evaluated. Of the 20 patients identified as
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eligible candidates, 12 were current smokers and eight were former smokers. Complete
smoking history documentation of the total of 20 patients was 65%. For LDCT orders, only six
were collected (30%) of the 20 eligible patients. For current smokers, five LDCT were ordered of
12 eligible patients (42%), while only one LDCT was ordered of the eight eligible patients who
were former smokers (12.5%).
PDSA Cycle One
PDSA cycle one revealed a decrease in smoking history documentation, but an increase
in LDCT orders placed from pre-intervention data (see Table 2). A total of six providers were
evaluated during this cycle. Of the 20 patients identified as eligible candidates, 13 were current
smokers and seven were former smokers. Complete smoking history documentation decreased
20% from preintervention to this PDSA cycle (40%; p=.204). Although, LDCT orders increased
by 5% (p=.736). For current smokers, six LDCT were ordered of 13 eligible patients (46%),
while only one LDCT was ordered of the seven eligible patients who were former smokers
(14%). Of the nine individuals with accurate documentation which met the criteria for LDCT, only
six received an order for LCDT (66.7%) (see Table 2).
Table 2. PDSA Cycle One Results
Pre-intervention
Smoking History
Documentation

PDSA Cycle 1

Assessed

Documented

Assessed

Documented

N=20
Current smokers
N=12
Former smokers
N=8

13 (65%)

N=20
Current smokers
N=13
Former smokers
N=7

8 (40%)

.204

6 (78%)

.411

2 (29%)

.608

9 (75%)
5 (63%)

Pre-intervention
Assessed

Total:
LDCT Ordered

P

N=20

Current smokers
N=12
Former smokers
N=8

PDSA Cycle 1

Ordered

6 (30%)
5 (41.6%)
1 (12.5%)
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Assessed

Total:

N=20

Current smokers
N=13
Former smokers
N=7

Ordered

P

7 (35%)

.736

6 (46%)

.821

1 (14%)

.919

PDSA Cycle Two
PDSA cycle 2 revealed a decrease in smoking history documentation and no change in
overall LDCT orders placed from preintervention data (Table 3). A total of five of the same
providers from cycle one was evaluated during cycle two. One of the six providers from cycle
one was no longer working at the clinic by cycle two. Of the 20 patients, seven were current
smokers and 13 were former smokers. It is important to note this cycle included more former
smokers than current smokers. When comparing the bar graph (Figure 2) there was a marked
decline in both complete documentation and LDCT orders for eligible patients.
Smoking history documentation decreased from 65% in the preintervention data to 40%
in this PDSA cycle (p=.113). LDCT orders overall maintained at 30% when compared to
preintervention data yet decreased from the PDSA cycle 1 improvement (35%). For current
smokers, three LDCT were ordered of seven eligible patients (57%; p=.960), while for former
smokers only three LDCT were ordered of 13 eligible patients (31%; p=.549). Eight total
patients had accurate documentation which met the criteria for a LDCT, but only three of the
eight identified received an order for LCDT (37.5%)
Table 3. PDSA Cycle Two Results
Pre-intervention
Smoking
History
Documentation

PDSA Cycle 2

Documented

Assessed

Documented

N=20
Current
smokers N=12
Former
smokers N=8

13 (65%)

N=20
Current smokers
N=7
Former smokers
N=13

8 (40%)

.113

4 (57%)

.617

4 (31%)

.646

9 (75%)
5 (63%)

Pre-intervention

LDCT Ordered

p

Assessed

PDSA Cycle 2

p

Assessed

Ordered

Assessed

Ordered

N=20
Current smokers
N=12
Former smokers
N=8

6 (30%)

N=20
Current smokers
N=7
Former smokers
N=13

6 (30%)

1.0

3 (57%)

.960

3 (31%)

.549

5 (41.6%)
1 (12.5%)
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Figure 2. Comparison of accurate smoking history documented and LDCT orders.

Note: Documentation significantly higher in cycle 4 compared to both cycle 2 (p=.022) and cycle
3 (p=.010)

PDSA Cycle Three
PDSA cycle 3 revealed an increase in smoking history documentation and an increase in
overall LDCT orders placed from preintervention data. Of the 20 eligible patients, 12 were
current smokers and eight were former smokers. Smoking history documentation increased
from 65% in the preintervention date to 80% in this PDSA cycle (p=.288). LDCT orders overall
increased by 20% when compared to preintervention data (p=.110). Seven LDCT were ordered
for current smokers, out of 12 eligible patients (58%). Five LDCT was ordered for former
smokers of the eight eligible patients (62.5%). Of the sixteen patients that had accurate
documentation which met the criteria for LDCT, only 12 received an order for LCDT (68.8%)
(Table 8). When comparing preintervention data to cycle three, there was a significant
improvement in LDCT ordered on former smokers (p=.039*). Of the total of 11 LDCT accounted
for during this cycle, two were included that were offered but declined by the patient.

*

p value less than .05 is statistically significant

32

Table 4. PDSA Cycle Three Results
Pre-intervention
Smoking History
Documentation

PDSA Cycle 3

Assessed

Documented

Assessed

Documented

N=20
Current smokers
N=12
Former smokers
N=8

13 (65%)

N=20
Current smokers
N=12
Former smokers
N=8

16 (80%)

.288

10 (83%)

1.00

6 (75%)

.608

9 (75%)
5 (63%)

Pre-intervention

LDCT Ordered

p

PDSA Cycle 3

p

Assessed

Ordered

Assessed

Ordered

N=20

6 (30%)

N=20

12 (60%)

.110

7 (58%)

.682

5 (62.5%)

.039*

Current smokers
N=12
Former smokers
N=8

5 (41.6%)
1 (12.5%)

Current smokers
N=12
Former smokers
N=8

Summary of Findings
Smoking history documentation throughout the study improved significantly overall (p =
.039*) (Table 5). Documentation was significantly higher in PDSA cycle 3 compared to both
PDSA cycle 1 (p=.022*) and PDSA cycle 2 (p=.010*; Figure 2). These findings suggest that
improved communication between the MA and the providers when smoking history
documentation is completed may have been the most effective intervention for implementation
in this specific primary care setting. Current smokers throughout all cycles did not have a
significant improvement in smoking history documentation (p = .369; Table 5). Former smokers
did not have a significant improvement although trended towards improvement (p = .185; Table
5). Due to increased awareness of smoking risk, it was expected that current smokers would
have a greater improvement in LDCT orders.
LDCT orders did not improve significantly over the study (p= .30), although this trended
towards improvement across cycles (Table 3). Former smokers were found to have a
considerable improvement in LDCT orders through the study (p= .089) versus current smokers
(p= .979; Table 6). Of the 80 patients identified in the study, they all met eligibility criteria for
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LDCT screening, but only 30 had LDCT ordered (37.5%). The patients with both smoking
histories documented and LDCT ordered were not statistically significant (p=.079). When
breaking down smoking status with accurate documentation and LDCT orders, current smokers
had a greater improvement compared to former smokers although not statistically significant (p=
.131; Table 8). †
Table 5. Accurate smoking history documentation including pack-years
Total
Pre intervention
PDSA Cycle 1
PDSA Cycle 2
PDSA Cycle 3

Current
Smokers

p

N=20

13 (65%)

N=20

9 (45%)

N=20

8 (40%)

N=20

16 (80%)

.039*

N=12

9 (75%)

N=13

7 (54%)

N=7

4 (57%)

Former
Smoker

p

.369

N=12 10 (83%)

N=8

4 (50%)

N=7

2 (29%)

N=13

4 (31%)

N=8

6 (75%)

p

.185

Table 6. LDCT Ordered
P

Total
Pre intervention
PDSA Cycle 1
PDSA Cycle 2
PDSA Cycle 3

N=20

6 (30%)

N=20

7 (35%)

N=20

6 (30%

N=20

11 (55%)

Current
Smokers

P

N=12 5 (41.6%)

.30

N=13

6 (46%)

N=7

3 (43%)

N=12

7 (55%)

Former
Smoker

p

N=8 1 (12.5%)

.979

N=7

1 (14%)

N=13

3 (31%)

N=8

5 (50%)

.089

Table 7. Comparison of smoking history documentation and screenings ordered across cycles
(N=80)
Preintervention
(n = 20)

PDSA 1
(n = 20)

PDSA 2
(n = 20)

PDSA 3
(n = 20)

13 (65%)
7 (35%)

9 (45%)
11 (55%)

8 (40%)
12 (60%)

16 (80%)
4 (20%

.039

6 (30%)
14 (70%)

7 (35%)
13 (65%)

6 (30%)
14 (70%)

11 (55%)
9 (45%)

.30

p

Smoking history documented

Yes
No
LDCT orders
Ordered
Not ordered

* †

p value less than .05 is statistically significant
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Table 8. Comparison of patients who had smoking history documented and eligible for LDCT
also had LDCT orders.
Preintervention
PDSA 1
PDSA 2
PDSA 3
P
(n = 13)+
(n = 9)
(n = 8)
(n = 16)
Smoking history documented
and LDCT ordered
Current
Former

5 (83.3%)

6 (66.7%)

3 (37.5%)

11 (68.8)

.071

4
1

5
1

1
2

6
5

.131
.459

+

N value was gathered from all individuals with complete smoking history documentation that were all
deemed eligible for LDCT order.

Discussion
Documentation of complete smoking history is challenging in primary care offices across
the nation. Lung cancer screening requires complete smoking history documentation to
determine eligibility, which possibly leads to a nationally low screening rate of 5.7%. The
literature supports the use of clinical reminders via electronic or physical form to increase
documentation and subsequently LDCT orders (Modin et al., 2017). The purpose of this QI
project was to evaluate rates of complete smoking history documentation and LDCT orders in
the primary care setting after implementing evidence-based interventions to improve
documentation and screenings rates. The goal was to improve smoking history documentation
and increase lung cancer screening orders by 3% for all eligible patients identified in the clinic.
This goal was exceeded, there was a 15% increase in both smoking history documentation
(65% to 80%) and LDCT orders (30% to 55%) from preintervention data to final data collection
in PDSA cycle 3.
Smoking cigarettes is the number one risk factor for developing lung cancer, it is linked
to 80 to 90% of all lung cancer-related deaths (CDC, 2019). Within five years of quitting smoking
there is a 39% lower risk of developing lung cancer, and within 10 years of quitting the risk of
developing lung cancer is half that of a person who has continued to smoke (ACS, 2019; Mong
et al., 2011; Tindle, et al., 2018). However, the risk is still greater than a never smoker so
clinicians must be mindful of this risk and eligibility for LDCT. The clinicians need to be alert that
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these individuals are at risk and can be missed, and future studies must dive into this issue
further. There is very little literature comparing current smokers versus former smokers for lung
cancer screening. Yet, identifying eligible patients is the leading modifiable factor to low
screening rates which is hindered by the incomplete documentation of smoking history (Pham et
al., 2018).
Smoking history documentation in this study had a significant improvement overall, yet
no significant improvement in either current or former smokers when assessed exclusively. Due
to increased awareness of smoking risk, it was expected that current smokers would have a
greater improvement in LDCT orders, although this study found that former smokers had a
considerable improvement in LDCT orders. This may have been a unique finding of this study,
yet this could be due to identifying more former smokers by using an inclusive question when
gathering smoking history.
The results of this study suggest that adequate education and the use of clinical
reminders can provide improvement in documentation and screening rates. This is consistent
with previous studies showing that the use of clinical reminders cannot only increase
documentation but, consequently increase LDCT orders. The use of clinical reminders had
considerable improvement in cycle 3 for former smokers, which was a unique finding in this
study. Although quitting smoking can lower the risk of being diagnosed with cancer, former
smokers are still at higher risk than those who have never smoked. Both current and former
smokers must be screened at substantially higher rates. The sole purpose of lung cancer
screening is to improve morbidity and mortality outcomes by improving prognosis and
increasing treatment options.
Recommendations for Practice
After the implementation of three evidence-based strategies, rates of complete smoking
history documentation and LDCT orders improved. It is recommended that a combination of
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these interventions be used to improve lung cancer screening in the chosen clinic, as well as
other primary care settings. Improved communication between the MA and providers in
combination with complete smoking history was the most effective intervention for this study.
For this primary care practice, visual cues of clinical reminders were effective. Depending on
independent factors in each setting may warrant different types of clinical reminders. Education
to the staff on clinical guidelines for screening is important because without adequate
knowledge staff will not know who to screen and/or how to document.
Further investigation using a longitudinal study design to analyze pre-and postimplementation of EMR reminders. Incorporating EMR reminders of smoking status with packyears on the patient’s main profile could be effective in provider compliance of LDCT orders.
Implementing a standard smart phrase to be used with the Epic EHR could create awareness of
the LDCT discussion, with additional information on discussions if the patient declines.
Implication to Research
More PDSA cycles with ongoing interventions could be used to explore the success of
further interventions. Future studies could gather data on LDCT completion rates and the barrier
to completing, including patient-specific barriers. Patient questionnaires could be used to
explore the reason for not completing screening. These barriers could be used to incorporate
further PDSA cycles directed towards patient-identified barriers. Incorporating EMR reminders
on the patient’s main profile could be effective in provider compliance with LDCT orders. Future
studies could focus on the effectiveness of implementing EMR reminders for LDCT orders.
Limitations
The sample size for each PDSA cycle was small, which can limit the ability to detect a
statistical significance that would be found with a larger sample size. In addition, the fact that
documentation of smoking history has not been standardized in this setting creates the potential
for inaccurate rates of screening and risk discussions. Currently, the providers and MAs can
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document in multiple places including the smoking history tab or within the note. Both places
were assessed when auditing charts, but the lack of a standardized location for documentation
creates barriers to auditing for screening. If the provider screens the patients and they agree to
have a LDCT, an order is placed. Yet, if the provider screens and the patient declines
screening, without documentation of the discussion it is assumed it was not addressed. Without
standard documentation on screening discussion, it is unclear if screening discussion occurred.
Requiring providers to document in a designated area of the EHR could worsen time constraints
but incorporating a smart phrase could be more time effective for the provider.
Conclusion
It is estimated that nationally every day in 2022, 648 Americans will be diagnosed with
lung cancer and 356 lung cancer-related deaths will occur. Lung cancer screening has an
estimated 1.5% positivity rate, meaning for every 1,000 people screened, 15 will be diagnosed
with lung cancer (Young, Fairchild & Hefner, 2017). An LDCT scan can reduce lung cancer
mortality by 20% by detecting early cancer when treatment is more effective (De Koning, et al.,
2020). The number one cause of lung cancer is cigarette smoking and obtaining complete
smoking history remains the most important technique in identifying candidates for lung cancer
screening. Despite the national target goal for screening of 7.5%, only 5.7% of eligible
Americans nationwide were screened in 2021, which remains substantially lower than all-over
cancer screening rates. Overcoming the barriers to lung cancer screening is essential to
increasing screening rates.
This study focused on evaluating rates of complete smoking history documentation and
LDCT orders after implementing interventions to improve documentation and screenings rates.
Results of this study suggest that through the combination of interventions used, with collective
efforts and attention there was a significant increase in smoking history documentation.
Although, individual interventions (poster, educational session, and clinical reminders) did not
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have a significant effect on smoking history documentation. LDCT orders were not affected
considerably by the interventions used in combination with each other or individually. The
results of this project suggest that the use of clinical reminders had the greatest improvement in
LDCT orders overall and had a considerable improvement in former smokers’ lung cancer
screening orders within the chosen clinic. Incomplete documentation of smoking history adds
difficulty to identifying eligible patients which is observed to be the leading factor in low
screening rates. Ultimately increasing smoking history documentation, can lead to increased
LDCT's which can decrease morbidity and mortality of lung cancer.
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Figures
Figure 3. Survey Findings
Q1. Select all that apply: Of the following options, which do you associate the barriers to
provide lung cancer screening?

Q2. Rank in order of associate the barriers to providing lung cancer screening. Number 1
is the most associated barrier and Number 7 is the least associated barrier
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Q3. Of the following options, which question do you use when asking about smoking
history?

Q4. When assessing smoking history, do you document pack years?

Q5. Do you look at your Care Gaps during each visit?

Q6. What process or processes within the clinic do you believe could be improved to
ensure all eligible patients are screened?
• Preventative health visit only- Must make separate clinic visit for additional chronic issues.
• Adding education flyers in patient rooms
• Using tablets for self-administered screening, or staff administration of screening with a
scripted question.

47

Appendices
Appendix A. Informed Consent
Dear Providers at Polk Dalton,
I am contacting you from the University of Kentucky, on behalf of myself, Destinee Rein to invite
you to participate in a research study, “Improving Smoking History Screening and Documentation
to Increase Lung Cancer Screenings in Primary Care Clinics.” The purpose of this quality
improvement project is to investigate the disparity in thorough screening and documentation of
current and former smokers. Furthermore, to increase smoking history documentation and lowdose computed tomography (LDCT) orders on eligible patients who meet screening criteria in a
primary care setting.
The Principal Investigator is Destinee Rein a faculty member in the Doctor of Nursing Practice
Program at the University of Kentucky College of Nursing.
If you agree to participate in the study, you will be asked to complete an online survey on Qualtrics
that asks you to provide answers to several question items, in the form of select all that apply,
yes/no and fill in the blank. Although you may not get personal benefit from taking part in this
research study, your responses may help us understand more about the barrier to screening for
lung cancer. Some volunteers experience satisfaction from knowing they have contributed to
research that may benefit others in the future. In addition to this survey, an educational
intervention will follow educating on the specific objectives of this study. I will be discussing the
barriers identified in the clinic to obtaining accurate smoking history documentation, how to
combat those barriers and increase compliance on documentation, as well as educating on
USPSTF recommendations on lung cancer screening.
If you do not want to be in the study, there are no other choices except not to take part in the
study.
The survey/questionnaire will take about 3 minutes to complete. I hope to receive completed
questionnaires from about 20 people, so your answers are important to us. Of course, you have
a choice about whether to complete the survey/questionnaire, but if you do participate, you are
free to skip any questions or discontinue at any time. You will not be penalized in any way for
skipping or discontinuing the survey. An educational session will concur with staff meetings each
month on the following objectives of the study. A total of 2 educational sessions will concur
throughout this project. Each educational session will take a max of 15 minutes to complete.
We make every effort to safeguard your data once received on our servers via Qualtrics. Given
the nature of online surveys, as with anything involving the internet, we can never guarantee the
confidentiality of data still en route to us. Qualtrics is a secure, web-based application designed
exclusively to support data capture for research studies. Your responses will be anonymous.
Results of this research will be reported as summarized data and will not contain any identifiable
individual data. For this study, you will not be asked to provide a name, email address, or any
identifying information.
Should you have any questions you may contact Destinee Rein, the Principal Investigator, at
drca229@uky.edu or per telephone at (502) 216-6986. If you have complaints, suggestions, or
questions about your rights as a research volunteer, contact the staff in the University of Kentucky
Office of Research Integrity at 859-257-9428 or toll-free at 1-866-400-9428
Please be aware, while we make every effort to safeguard your data once received from the online
survey company, given the nature of online surveys, as with anything involving the Internet, we
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can never guarantee the confidentiality of the data while still on the survey company’s servers, or
while en route to either them or us. It is also possible the raw data collected for research purposes
will be used for marketing or reporting purposes by the survey/data gathering company after the
research is concluded, depending on the company’s Terms of Service and Privacy policies. By
completing the survey, you are indicating that you are at least 18 years old, have read and
understood this consent form, and agree to voluntarily participate in this research study.”
Thank you in advance for your assistance with this important project. To ensure your
responses/opinions will be included, please submit your completed survey/questionnaire by
December 10, 2021.

https://qfreeaccountssjc1.az1.qualtrics.com/jfe/form/SV_b0YpKVuTOlucCLI
Sincerely,
Destinee Rein
College of Nursing, University of Kentucky
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Appendix B. Survey Questions
Assessing Barriers to Smoking History Documentation
1. Unfamiliarity with screening guidelines
2. Unfamiliarity with eligible patients
Select all that apply: Of the following
3. Time constraints in conducting shared decision making
options, which do you associate the
4. Lack of patient awareness of screening guidelines
barriers to providing lung cancer
5. Lack of using inclusive language during screening
screening?
6. Unfamiliarity with the management of abnormal results
7. Lack of smoking history documentation
1. Unfamiliarity with screening guidelines
Rank in order of associated barriers to 2. Unfamiliarity with eligible patients
providing lung cancer screenings.
3. Time constraints in conducting shared decision making
Number 1 is the most associated barrier 4. Lack of patient awareness of screening guidelines
and Number 7 is the least associated 5. Lack of using inclusive language during screening
barrier
6. Unfamiliarity with the management of abnormal results
7. Lack of smoking history documentation
1. Do you smoke?
Of the following options, which question
2. Do you smoke or have you ever smoked?
do you use when asking about smoking
3. Do you smoke or have you smoked in the past for 3 months
history?
consecutively?
When assessing smoking history, do you 1. Yes
document pack years?
2. No
Do you look at your Care Gaps during 1. Yes
each visit?
2. No
Open Answer: What process or
processes within the clinic do you believe
could be improved to ensure all eligible
patients are screened?
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Appendix C. Lung Cancer Poster

51

Appendix D. Eye-catching Clinical Reminder

LUNG CANCER
SCREENING
CANDIDATE
Appendix E. Process Map
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